about
Lack of salt-inducible kinase 2 (SIK2) prevents the development of cardiac hypertrophy in response to chronic high-salt intake.Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action.Drug-eluting stents: results, promises and problems.Characterization of the interaction of the novel antihypertensive etamicastat with human dopamine-β-hydroxylase: comparison with nepicastat.Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: a comparison with carbamazepine, oxcarbazepine and lacosamide.Sirolimus and paclitaxel provoke different vascular pathological responses after local delivery in a murine model for restenosis on underlying atherosclerotic arteries.Role of P-glycoprotein and permeability upon the brain distribution and pharmacodynamics of etamicastat: a comparison with nepicastat.Apolipoprotein C-I is crucially involved in lipopolysaccharide-induced atherosclerosis development in apolipoprotein E-knockout mice.Early systemic inflammatory response to drug-eluting stents implantation: the heart of the difference? Editorial to: "Comparison of changes in early inflammatory markers between sirolimus- and paclitaxel-eluting stent implantation" by Li et al.Carbamazepine and oxcarbazepine, but not eslicarbazepine, enhance excitatory synaptic transmission onto hippocampal CA1 pyramidal cells through an antagonist action at adenosine A1 receptors.Targeting pharmacoresistant epilepsy and epileptogenesis with a dual-purpose antiepileptic drug.Blood pressure decrease in spontaneously hypertensive rats folowing renal denervation or dopamine β-hydroxylase inhibition with etamicastat.Cardiovascular safety pharmacology profile of etamicastat, a novel peripheral selective dopamine-β-hydroxylase inhibitor.Histopathologic alterations following local delivery of dexamethasone to inhibit restenosis in murine arteries.Increased arterial blood pressure and vascular remodeling in mice lacking salt-inducible kinase 1 (SIK1).Activation of nuclear receptor Nur77 by 6-mercaptopurine protects against neointima formation.The effect of interleukin-10 knock-out and overexpression on neointima formation in hypercholesterolemic APOE*3-Leiden miceDiscovery of a Potent, Long-Acting, and CNS-Active Inhibitor (BIA 10-2474) of Fatty Acid Amide HydrolaseGenetic Inflammatory Factors Predict Restenosis After Percutaneous Coronary InterventionsInhibition of neointima formation by local delivery of estrogen receptor alpha and beta specific agonistsShort-term dexamethasone treatment inhibits vein graft thickening in hypercholesterolemic ApoE3Leiden transgenic miceLipoprotein Lipase Gene Polymorphisms and the Risk of Target Vessel Revascularization After Percutaneous Coronary InterventionBlood pressure-decreasing effect of etamicastat alone and in combination with antihypertensive drugs in the spontaneously hypertensive ratCarbamazepine aggravates absence seizures in two dedicated mouse modelsPreclinical pharmacological evaluation of the fatty acid amide hydrolase inhibitor BIA 10-2474
P50
Q35154059-0F613D43-D9D9-4B50-88E9-7E3093955074Q35664957-95761173-439F-47CB-96CC-2CA472DD8C31Q36049064-CB5C7AA1-B4AC-4652-AEC6-A1CC4BFDE3E9Q38914106-76E86123-21BB-48E7-9AB3-40499F7A4F14Q38954421-71549A91-06E3-4B8F-8ED2-6C793D89FCEAQ41390902-11800548-A3CF-4461-A414-BC2B56CB9310Q42476216-7584A6D1-DD35-4237-8602-723C1CF95C54Q43976830-9FA39739-2406-40CC-9621-986989414ABEQ46190137-878B0482-0C50-403F-88B3-E556584E1089Q48341898-D3492DDF-EFE0-49D5-9776-A516D92F73E4Q48424510-500C8902-9353-49C5-ACF7-11F556CC50FDQ50991341-BDF00F4C-9241-47CE-AD74-7576D822AF7CQ51060581-11892B35-5E61-40EB-A54A-8433CA81B627Q51399468-7FFD570C-A60A-404A-BAA5-42DCB12EDAAEQ52978630-B3FD47EB-8A9F-4570-BF63-3E183726E25FQ53575755-22E65AF9-3428-41D2-AD04-7E53943DB542Q56999050-C346947A-A267-4BC1-8A0A-1193B57D1369Q57801957-6A41B9AA-9C42-4B42-BF37-7898EB1C6FB1Q59261087-76BF3194-EC06-4848-A9B7-CC2D78C7CA31Q63915495-E8683FE9-AA73-4BDF-ABF4-09AFDFE04132Q63915501-F3D5010A-1A39-44B8-93E7-C74E85836294Q63915504-97C7644F-8B33-4C3E-AA85-9CB7F63D0B79Q85723642-E1DEA7E1-9878-436D-83B0-453F8383DA1FQ86231823-45AB1E37-A6B5-4FE0-95F4-8CDDFAB0C180Q92412421-CF4CD25F-B4E1-48BF-944B-4227AC193AAF
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Nuno Miguel Pires
@ast
Nuno Miguel Pires
@en
Nuno Miguel Pires
@es
Nuno Miguel Pires
@nl
Nuno Miguel Pires
@sl
type
label
Nuno Miguel Pires
@ast
Nuno Miguel Pires
@en
Nuno Miguel Pires
@es
Nuno Miguel Pires
@nl
Nuno Miguel Pires
@sl
prefLabel
Nuno Miguel Pires
@ast
Nuno Miguel Pires
@en
Nuno Miguel Pires
@es
Nuno Miguel Pires
@nl
Nuno Miguel Pires
@sl
P106
P21
P31
P496
0000-0001-5244-8550